Thus, it is reasonable to believe that besides combing PI3K-Akt inhibitors (Konstantinopoulos et al. 2019), PARP-targeted drugs combining YARS inhibitors might also be a potential therapeutic option against GC. This evidence concerns the gene YARS1 and gastric cancer.